Roivant Sciences Ltd.
ROIV · Nasdaq · United Kingdom
Share price · ROIV
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ROIV's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 8 Sep 2026+18.8%
- 28 Aug 2026-7.6%
- 21 May 2026-4.7%
- 20 May 2026+14.9%
- 9 Feb 2026+7.2%
- 6 Feb 2026+22.1%
- 13 Jan 2026+5.8%
Nothing announced by ROIV that day or the session before.
- 16 Dec 2025+4.7%
Nothing announced by ROIV that day or the session before.
- 11 Dec 2025+5.4%
Share of unusual movement by asset
For each asset, the share of ROIV's own-move activity since 10 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
brepocitinib(Lisraya) | Approved | TYK2/JAK1Small molecule | PsoriasisDermatomyositisNon-Infectious UveitisCutaneous SarcoidosisLichen PlanopilarisIdiopathic Inflammatory Myopathies |
| Phase 3 | FcRnMonoclonal antibody | Rheumatoid ArthritisMyasthenia GravisGraves' DiseaseChronic Inflammatory Demyelinating PolyneuropathySjögren's Disease | |
| Phase 3 | Soluble guanylate cyclaseSmall molecule | Pulmonary Hypertension Associated with Interstitial Lung Disease |
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (3)
2028 (3)
2029 (1)
January 2029 (1)
What to watch
2030 (1)
March 2030 (1)
What to watch
Regulatory and conference events
(7)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $35M | $146M | $1.6B+ $2.6B short-term inv. | $192M$594M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $1.4M | $202M | $1.3B+ $2.6B short-term inv. | $190M-$271M operating cash flow | report ↗ |
| 2025-Q4 | $2.0M | $165M | $1.5B+ $3.1B short-term inv. | $266M-$196M operating cash flow | report ↗ |
| 2025-Q3 | $1.6M | $165M | $1.2B+ $3.1B short-term inv. | $114M-$186M operating cash flow | report ↗ |
| 2025-Q2 | $2.2M | $153M | $1.2B+ $3.3B short-term inv. | $223M-$204M operating cash flow | report ↗ |
| 2024-Q4 | $9.0M | $142M | $2.0B+ $3.2B short-term inv. | —-$207M operating cash flow | report ↗ |
| 2024-Q3 | $4.5M | $143M | $2.0B+ $3.4B short-term inv. | $230M-$267M operating cash flow | report ↗ |
| 2024-Q2 | $55M | $133M | $5.7B | —-$193M operating cash flow | report ↗ |
| 2023-Q4 | $37M | $124M | $6.7B | —-$210M operating cash flow | report ↗ |
| 2023-Q3 | $37M | $132M | $1.4B | $304M-$196M operating cash flow | report ↗ |
| 2023-Q2 | $22M | $125M | $1.4B | $292M-$250M operating cash flow | report ↗ |
| 2022-Q4 | $17M | $126M | $1.5B | $352M-$223M operating cash flow | report ↗ |
| 2022-Q3 | $13M | $132M | $1.6B | $292M-$190M operating cash flow | report ↗ |
| 2022-Q2 | $4.3M | $136M | $2.0B | $332M-$252M operating cash flow | report ↗ |
| 2021-Q4 | $24M | $153M | $2.2B | $285M-$268M operating cash flow | report ↗ |
| 2021-Q3 | $14M | $254M | $2.5B | $208M-$121M operating cash flow | report ↗ |
Annual history (6 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-FY | $8.3M | $682M | $1.4B+ $2.9B short-term inv. | $75M-$750M operating cash flow | report ↗ |
View 5 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $29M | $550M | $2.7B+ $2.2B short-term inv. | $43M-$839M operating cash flow | report ↗ |
| 2024-FY | $125M | $502M | $6.6B+ $0 short-term inv. | —-$765M operating cash flow | report ↗ |
| 2023-FY | $61M | $525M | $1.7B | $252M-$843M operating cash flow | report ↗ |
| 2022-FY | $55M | $483M | $2.1B | $211M-$678M operating cash flow | report ↗ |
| 2021-FY | $24M | $237M | $2.1B | $202M-$552M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 129 sales ($959.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | QVT Financial LP · Director by Deputization | Other (see filing) | 2,635,169 | — | — | Form 4 |
| 2026-11-17 | Gold Daniel Allen · director | Other (see filing) | 2,635,169 | — | — | Form 4 |
| 2026-11-17 | MANCHESTER KEITH S · director | Other (see filing) | 2,635,169 | — | — | Form 4 |
| 2026-11-17 | QVT Financial LP · Director by Deputization | Other (see filing) | 15,969 | — | — | Form 4 |
| 2026-11-17 | Gold Daniel Allen · director | Other (see filing) | 15,969 | — | — | Form 4 |
| 2026-11-17 | MANCHESTER KEITH S · director | Other (see filing) | 15,969 | — | — | Form 4 |
| 2026-11-17 | QVT Financial LP · Director by Deputization | Other (see filing) | 385,620 | — | — | Form 4 |
| 2026-11-17 | Gold Daniel Allen · director | Other (see filing) | 385,620 | — | — | Form 4 |